Article Text

Download PDFPDF
EV286/#550  Hormone receptors expression in high-grade epithelial ovarian cancers: a retrospective study
  1. Alizée Lebeau1,
  2. Margot Lenom2,
  3. Louis Lapaille2,
  4. Elodie Gonne2,
  5. Maude Piron2,
  6. Frederic Goffin3,
  7. Athanasios Kakkos3,
  8. Sophie Shoenen3,
  9. Katty Delbecque4,
  10. Clémence Pleyers5,
  11. Laurence Seidel6,
  12. Pierre Lovinfosse7,
  13. Denis Danthine8,
  14. Frederic Kridelka3 and
  15. Christine Gennigens2
  1. 1CHU de Liège, Department of Medical Oncology and Gynecology, Liege, Belgium
  2. 2CHU de Liège, Department of Medical Oncology, Liege, Belgium
  3. 3CHU de Liège, Department of Gynecology and Obstetrics, Liege, Belgium
  4. 4CHU de Liège, Department of Pathology, Liege, Belgium
  5. 5CHU de Liège, Department of Radiotherapy Oncology, Liege, Belgium
  6. 6CHU-ULiège, Biostatistics and Research Method Center (b-stat), Liege, Belgium
  7. 7CHU de Liège, Division of Nuclear Medicine and Oncological Imaging, Liege, Belgium
  8. 8CHU de Liège, Department of Radiology, Liege, Belgium

Abstract

Introduction Under the influence of their receptors, progesterone is well known for its antagonistic effects to estrogen, which promotes tumor cell proliferation. The roles of estrogen and progesterone are less clear in ovarian cancer than in other hormone-dependent cancers such as breast or endometrial tumors. Our objective was to evaluate immunopositivity for progesterone (PR) and estrogen receptors (ER) in patients with high-grade epithelial ovarian cancer (HGEOC).

Methods Between January 2018 and November 2023, we conducted a retrospective study of 104 patients with HGEOC at the University Hospital of Liège. Hormone receptors expression was detected by immunohistochemistry on biopsies and/or surgical specimens. A positivity threshold was set at 10% of positive tumor cells. The median follow-up was 25.1 months. The impact of ER and PR expression on OS and PFS was evaluated by univariate COX regression models.

Results Our study reports that 91.0%, 34.1% and 32.6% of HGEOC were ER-positive, PR-positive and positive for both receptors, respectively. ER expression <10% is associated with a statistically significant higher risk of death and relapse: OS (HR: 8.00; [95% CI: 2.48-25.6]; p=0.0005) and PFS (HR: 5.88; [95% CI: 3.55-18.2]; p=0.0022). PR expression <10% has no impact on OS and PFS. The association of ER and PR was analyzed by distinguishing 4 groups (ER+/PR+; ER+/PR-; ER-/PR+; ER-/PR-). Positive ER has higher OS (p=0.0052) and PFS (p=0.016) regardless of PR status.

Conclusion/Implications The absence of ER expression in HGEOC is associated with a poorer prognosis. These findings need further explorations.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.